In a nutshell This study evaluated the effectiveness and safety of the BendaEAM (bendamustine, etoposide, cytarabine, melphalan) in patients with lymphoma undergoing autologous stem cell transplantation (auto-SCT). This study concluded that BendaEAM is a feasible option for these patients, with minimal side effects. Some background High-dose...
Read More
In a nutshell This study investigated the development of Hodgkin lymphoma (HL) above and below the diaphragm. Patients with HL above the diaphragm had better survival and response to treatment. Some background HL is a type of cancer which affects the lymph nodes. HL may develop above or below the diaphragm (a muscle which helps you...
Read More
In a nutshell This study investigated the effectiveness and safety of brentuximab vedotin (Adcetris) in patients with relapsed (cancer recurrence) or refractory (does not respond to treatment) Hodgkin’s lymphoma (HL). This study concluded that brentuximab vedotin was effective and well-tolerated in these high-risk patients. Some background The...
Read MoreIn a nutshell This study investigated the effects of brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma after stem cell transplant. Brentuximab vedotin appeared to be effective and safe for these patients. Some background Many patients with Hodgkin lymphoma (HL) are cured by standard therapies. However, some patients lose...
Read More
In a nutshell This study assessed the development of osteonecrosis in patients who were treated for Hodgkin lymphoma. The main finding was that patients treated with steroids were more likely to develop osteonecrosis. Some background Hodgkin lymphoma is a type of cancer which affects system. Many patients with Hodgkin lymphoma (HL) are...
Read More
In a nutshell This study investigated the development of hypothyroidism in patients with Hodgkin lymphoma after chemoradiation therapy. Patients were more likely to develop hypothyroidism after intensity modulated radiation therapy than after 3-dimensional conformal radiation therapy. Some background Patients with Hodgkin lymphoma (HL) are commonly...
Read More
In a nutshell This article reviewed new treatment options for patients with relapsed Hodgkin’s lymphoma (HL). Some background The most common front-line (primary) chemotherapy regimen for the treatment of HL is ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). 88 – 94% of patients with HL respond to this treatment. However, 10...
Read More
“Always trust your gut. Don’t leave your treatment in the hands of someone that you don’t trust or that does not seem like a team player. Yes, they are all smart—even brilliant—but read, read, read, and question them at every corner and challenge the standard of care. Exercise, healthy eating, learning the ropes of insurance, mediation/prayer...
Read More
In a nutshell This article reviewed the use of proton therapy in adult patients with lymphoma in the mediastinum (the middle section of the chest around the lungs). Some background Many lymphomas are found in the mediastinum, next to the heart, lungs, and breasts. These organs are especially sensitive to chemotherapy and radiation therapy. In adult...
Read More
In a nutshell This study evaluated the risk of acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) development in patients with lymphoma and myeloma after an autologous stem cell transplant (autoSCT). This study concluded that this risk is quite high after autoSCT in these patients. Some background AML and MDS are known long-term...
Read MoreIn a nutshell This study is investigating the effectiveness of T-cell immunotherapy in Hodgkin’s lymphoma (HL) patients with tumors that are EBV+ (positive for Epstein-Barr virus). This study is recruiting in Duart, California, Washington, D.C., Baltimore, New York, Pittsburgh, and Houston. The details It is thought that individuals who have...
Read More
In a nutshell This study is investigating the effectiveness of ibrutinib (Imbruvica) for patients with relapsed or refractory (not responding to treatment) classical Hodgkin’s lymphoma (HL). Effectiveness is measured by the overall response rate (percentage of patients whose cancer shrinks or completely disappears after treatment). This study is...
Read More
